Q1 Earnings Estimate for EBS Issued By HC Wainwright

Emergent BioSolutions Inc. (NYSE:EBS) – Equities researchers at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Emergent BioSolutions in a research note issued to investors on Tuesday, March 4th. HC Wainwright analyst R. Selvaraju forecasts that the biopharmaceutical company will post earnings per share of $0.27 for the quarter. HC Wainwright currently has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Emergent BioSolutions’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Emergent BioSolutions’ Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at $0.04 EPS, Q4 2025 earnings at $0.18 EPS, FY2025 earnings at $0.32 EPS and FY2026 earnings at $3.83 EPS.

Several other equities research analysts also recently weighed in on EBS. StockNews.com downgraded Emergent BioSolutions from a “buy” rating to a “hold” rating in a report on Wednesday. Benchmark raised their price objective on Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, November 7th.

Emergent BioSolutions Trading Up 0.6 %

NYSE EBS opened at $5.84 on Thursday. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. Emergent BioSolutions has a twelve month low of $1.82 and a twelve month high of $15.10. The company has a market cap of $316.22 million, a price-to-earnings ratio of -1.42 and a beta of 1.62. The business’s fifty day moving average is $9.38 and its 200 day moving average is $9.00.

Emergent BioSolutions (NYSE:EBS) last released its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.40. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. The company had revenue of $194.70 million for the quarter, compared to the consensus estimate of $254.67 million. During the same quarter last year, the business posted ($0.77) EPS.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Covestor Ltd lifted its holdings in Emergent BioSolutions by 5,458.5% during the 4th quarter. Covestor Ltd now owns 2,946 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 2,893 shares during the period. SBI Securities Co. Ltd. acquired a new position in Emergent BioSolutions during the 4th quarter worth about $63,000. Stifel Financial Corp acquired a new position in Emergent BioSolutions during the 3rd quarter worth about $96,000. E Fund Management Co. Ltd. bought a new position in shares of Emergent BioSolutions in the 4th quarter worth about $98,000. Finally, FORA Capital LLC bought a new position in shares of Emergent BioSolutions in the 3rd quarter worth about $103,000. 78.40% of the stock is owned by institutional investors and hedge funds.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.